Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin: 2022-2025

Historic FCF Margin for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -127.77%.

  • ARS Pharmaceuticals' FCF Margin rose 57857.00% to -127.77% in Q3 2025 from the same period last year, while for Sep 2025 it was -60.25%, marking a year-over-year increase of 171154.00%. This contributed to the annual value of 14.57% for FY2024, which is 19815123.00% up from last year.
  • ARS Pharmaceuticals' FCF Margin amounted to -127.77% in Q3 2025, which was up 55.73% from -288.61% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' FCF Margin registered a high of 48.17% during Q4 2024, and its lowest value of -166,990.00% during Q2 2023.
  • In the last 3 years, ARS Pharmaceuticals' FCF Margin had a median value of -609.24% in 2025 and averaged -29,143.76%.
  • In the last 5 years, ARS Pharmaceuticals' FCF Margin plummeted by 16,548,224bps in 2023 and then skyrocketed by 16,552,660bps in 2024.
  • ARS Pharmaceuticals' FCF Margin (Quarterly) stood at -3,022.22% in 2022, then slumped by 16,548,224bps to -166,990.00% in 2023, then skyrocketed by 16,552,660bps to 48.17% in 2024, then surged by 57,857bps to -127.77% in 2025.
  • Its FCF Margin stands at -127.77% for Q3 2025, versus -288.61% for Q2 2025 and -512.14% for Q1 2025.